pembrolizumab,nt-i7
neoimmunetech,merck
['pembro', '1674p', 'neoimmune']
at #esmo22, we will be presenting a poster that suggests nt-i7 plus pembrolizumab combination treatment enhances infiltration of pd-1+ t cells in cold tumors. if you are attending esmo, please come and visit our poster 1674p, on sat 10 sept. 
NIT is a clinical-stage T cell-focused biotech company, dedicated to expand the horizon of Immuno-Oncology and infectious diseases